Peptide · Vial
Verified recordBPC 157
$9010mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Current batchBPC 004-012
Published result99.2% reported purity
EternaGen / TB5 004-016Peptide · Research use only
TB 500
$100CAD
A short peptide fragment related to thymosin beta 4 and explored in early tissue-repair research.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
TB 500, clearly explained.
A short peptide fragment related to thymosin beta 4 and explored in early tissue-repair research.
Overview
TB-500 usually refers to a small fragment of the much larger thymosin beta 4 peptide. Studies of the full peptide—especially topical eye studies—cannot be treated as proof for this fragment or another delivery method.
TB-500 commonly refers to the LKKTETQ fragment associated with thymosin beta 4. Full-length thymosin beta 4 is a 43-amino-acid peptide; the fragment and parent peptide must not be treated as the same molecular entity.- Format
- Vial
- Available strengths
- 10mg
- Batch
- TB5 004-016
- Purity
- 99.3%
Research at a glanceFragment-specific human evidence absent; full-length thymosin beta 4 evidence is not interchangeable
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- Confirm in batch record
- Molecular formula
- Confirm in batch record
- Molecular weight
- Confirm in batch record
- Storage and handling
- Consult the batch record for verified handling and storage conditions.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- TB5 004-016
- Purity
- 99.3%
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Actin and cell migration
Laboratory research on thymosin beta 4 examines actin sequestration, cell movement and tissue-response pathways.
Evidence so far: Mechanistic evidenceQuestion 02
Topical ophthalmic research
A phase 2 dry-eye study tested full-length thymosin beta 4 solution and did not meet its two primary endpoints.
Evidence so far: Formulation-specific human trialQuestion 03
TB-500 fragment
FDA reports no identified human exposure data for drug products containing the LKKTETQ fragment.
Evidence so far: Direct human evidence gapProposed mechanism
How researchers are investigating the mechanism.
Thymosin beta 4 binds actin and has been studied in cell migration and repair-related pathways. Even where the parent peptide shows biological activity, molecular identity, formulation and route determine whether a study is relevant to TB-500.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Randomized, double-masked phase 2 study of topical full-length thymosin beta 4
- What researchers saw
- The two primary endpoints were not significantly different; selected secondary outcomes were reported.
- Why that is not the whole story
- A topical full-length peptide study is not evidence for an injectable fragment.
Study 02FDA review of thymosin beta 4 fragment (LKKTETQ/TB-500)
- What researchers saw
- FDA reported no identified human exposure data and insufficient information to characterize harm.
- Why that is not the whole story
- Evidence for the parent peptide cannot fill a fragment-specific safety gap.
Evidence gaps
What remains unknown?
- Human pharmacology and safety of the TB-500 fragment are not established.
- Product naming can obscure whether the tested material is full-length thymosin beta 4 or a fragment.
- Route, formulation and purity data cannot substitute for molecularly matched clinical evidence.
Primary sources
Check the original sources.
- Primary full-length peptide studySosne and Ousler. Topical thymosin beta 4 phase 2 study. Clin Ophthalmol. 2015. PMID 26056426.
- Fragment-specific safety reviewU.S. FDA. Thymosin beta-4 fragment (LKKTETQ), also known as TB-500.
- Canadian public advisoryHealth Canada. Advisory on unauthorized injectable peptides, including TB-500. 2026.
Related products
Continue comparing.
Peptide · Vial
Verified recordGHK-CU
From CA$5550mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Current batchGHK 006-031
Published result99.5% reported purity
Peptide · Pen
Verified recordMOTS-c
From CA$20010mg40mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Current batchMOTS 005-021
Published result99.0% reported purity